



PRESS RELEASE

May 9, 2022

ZICCUM AB's Anna Lönn elected to NIIMBL Technical Activities Committee

Ziccum's Director of Development Anna Lönn has now been elected onto the Technical Activities Committee of the US National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), which will have its first meeting on May 23, 2022. NIIMBL, co-funded by the US Department of Commerce, funds and initiates a wide range of public-private research projects throughout the US.

Ziccum is one of a few European members invited to join NIIMBL, becoming a member in March 2021. NIIMBL is a public-private partnership that helps fund an ambitious range of research projects to accelerate biopharmaceutical innovation in manufacturing and supply. Members include industry, academic and government organizations within pharmaceutical manufacture and supply.

Anna Lönn, Ziccum's Development Director has been elected to NIIMBL's Technical Activities Committee (TAC) for the period 2022 - 2023. Anna, who joined Ziccum in September 2021 from TetraPak, has driven significant development throughout the company together with a highly skilled development team. Since September they have established the company's [expanded lab facilities and mRNA capabilities](#), and driven ahead its ambitious Quality by Design-led program of [technological development](#). Fellow NIIMBL members on the TAC include representatives from noted vaccine developers, biologics companies working on viral vectors and viral vaccines, and academics from leading US universities within bioprocesses and pharmaceuticals.

Ziccum Chairman Fredrik Sjövall: "The election of Anna really reflects her outstanding professionalism and expertise; she will bring fantastic qualities to fascinating work. We welcome the opportunities for networking and partnerships that TAC brings, and the possibilities for soft funding that can come through involvement with organizations like NIIMBL and CEPI (the Coalition for Epidemic Preparedness Innovation.) Our recent invitation from CEPI to submit an application for their soft-funded [project on innovation in thermostable vaccines](#), plus our ongoing work with NIIMBL, are all good examples of the awareness and interest in the industry around our technology. We look forward to making a valuable contribution."

READ MORE

- Read more about NIIMBL [here](#).
- Read more about LaminarPace [here](#).

For more information about Ziccum, please contact:

Fredrik Sjöval,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Certified Adviser

Erik Penser Bank AB
Mail: certifiedadviser@penser.se
Phone: +46 8 463 83 00

About Ziccum

Ziccum develops new thermostable versions of the world's most urgently needed, life-saving vaccines. The Company's patented technology, LaminarPace, enables the production of new, gently air-dried formulations that can be transported easily and cost-effectively, with no need for a costly and complicated cold chain, all the way from the factory to the last child in the last mile of the supply chain.

Attachments

[ZICCUM AB's Anna Lönn elected to NIIMBL Technical Activities Committee](#)